**APPENDIX TABLE 2.** Operating characteristics of improvement at week 4 to predict a shift to mild/no impairment (SDS subscale score ≤3) at week 8 (LOCF) for patients with marked/extreme impairment (≥7) at baseline: intent-to-treat population

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Early improvement threshold(% decrease) | Sensitivity | Specificity | PPV | NPV |
| Work/studies |
| Placebo  | 33.3 | 79.5 | 78.4 | 64.7 | 88.5 |
| Desvenlafaxine 50 mg/d | 40.0 | 77.1 | 78.2 | 77.1 | 78.2 |
| Desvenlafaxine 100 mg/d | 30.0 | 79.4 | 79.4 | 78.6 | 80.2 |
| All | 37.5 | 79.9 | 77.8 | 72.8 | 83.9 |
| Social life/leisure activities |
| Placebo  | 40.0 | 82.1 | 82.3 | 69.0 | 90.5 |
| Desvenlafaxine 50 mg/d | 37.5 | 77.7 | 76.0 | 74.4 | 79.2 |
| Desvenlafaxine 100 mg/d | 42.9 | 78.0 | 80.6 | 75.0 | 83.0 |
| All | 40.0 | 77.4 | 81.4 | 73.6 | 84.3 |
| Family life/home responsibilities |
| Placebo  | 37.5 | 78.1 | 76.0 | 60.5 | 88.1 |
| Desvenlafaxine 50 mg/d | 37.5 | 74.2 | 68.4 | 66.7 | 75.7 |
| Desvenlafaxine 100 mg/d | 42.9 | 75.8 | 81.5 | 75.2 | 82.0 |
| All | 37.5 | 77.0 | 74.0 | 65.8 | 83.1 |

LOCF, last observation carried forward; NPV, negative predictive value; PPV, positive predictive value; SDS, Sheehan Disability Scale.